A comprehensive view of Blood Disorders. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA grants Breakthrough Therapy Designation for Janssen’s talquetamab injectable antibody to treat relapsed or refractory multiple myeloma, a cancer of plasma cells; multiple myeloma affects 34,000 people in US annually, 176,000 worldwide
Published: June 30, 2022 by PR Newswire
FDA grants breakthrough therapy designation to Sanofi’s efanesoctocog alfa BIVV001 injectable to treat hemophilia A, a life-threatening bleeding disorder; hemophilia A is a lifelong condition that affects about one in 5,000 males, fewer females
Published: June 16, 2022 by Contify Life Science News
Pfizer partners with MorphoSys, Incyte to evaluate combined therapy to treat diffuse large B-cell lymphoma, a type of blood cancer; drugs include Pfizer’s experimental TTI-622, Morphosys and Incyte’s Monjuvi tafasitamab-cxix, Revlimid lenalidomide
Published: June 15, 2022 by SeeNews Pharmaceuticals
Charles River Laboratories partners with ASC Therapeutics to manufacture ASC618, a second-generation injectable gene therapy for hemophilia A; partnership will use Charles River’s end-to-end CDMO capabilities
Published: June 14, 2022 by Business Wire
Amgen and Kashiv Biosciences get US approval for Fylnetra, a biosimilar to Amgen’s injectable Neulasta pegfilgrastim to treat neutropenia resulting from chemotherapy; in 12 months ending March 2022, Neulasta biosimilars had US sales of US$1B
Published: June 07, 2022 by SeeNews Pharmaceuticals (

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count